Q1 EPS Forecast for Sangamo Therapeutics Boosted by Analyst

Sangamo Therapeutics, Inc. (NASDAQ:SGMO - Free Report) - Equities research analysts at HC Wainwright lifted their Q1 2025 earnings per share estimates for shares of Sangamo Therapeutics in a note issued to investors on Monday, April 7th. HC Wainwright analyst P. Trucchio now expects that the biopharmaceutical company will post earnings of ($0.04) per share for the quarter, up from their previous estimate of ($0.09). HC Wainwright currently has a "Buy" rating and a $10.00 target price on the stock. The consensus estimate for Sangamo Therapeutics' current full-year earnings is ($0.46) per share. HC Wainwright also issued estimates for Sangamo Therapeutics' Q2 2025 earnings at $0.03 EPS, Q3 2025 earnings at ($0.11) EPS, FY2025 earnings at ($0.12) EPS, FY2026 earnings at ($0.21) EPS and FY2027 earnings at ($0.05) EPS.

Sangamo Therapeutics (NASDAQ:SGMO - Get Free Report) last issued its earnings results on Monday, March 17th. The biopharmaceutical company reported ($0.11) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.09) by ($0.02). Sangamo Therapeutics had a negative return on equity of 264.16% and a negative net margin of 257.87%. The business had revenue of $7.55 million for the quarter, compared to analysts' expectations of $11.70 million.

SGMO has been the subject of a number of other research reports. Jefferies Financial Group reduced their target price on Sangamo Therapeutics from $7.00 to $3.00 and set a "buy" rating for the company in a report on Tuesday, December 31st. StockNews.com lowered shares of Sangamo Therapeutics from a "buy" rating to a "hold" rating in a report on Tuesday, December 24th. Truist Financial lowered their price target on shares of Sangamo Therapeutics from $7.00 to $5.00 and set a "buy" rating on the stock in a research report on Thursday, January 23rd. Wells Fargo & Company decreased their target price on shares of Sangamo Therapeutics from $3.00 to $2.00 and set an "equal weight" rating on the stock in a research note on Tuesday, December 31st. Finally, Royal Bank of Canada reaffirmed a "sector perform" rating and issued a $2.00 price target on shares of Sangamo Therapeutics in a report on Tuesday, March 18th. Three research analysts have rated the stock with a hold rating and four have issued a buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average price target of $5.17.

Sangamo Therapeutics Stock Performance

Shares of SGMO traded down $0.03 during mid-day trading on Thursday, hitting $0.72. 4,741,044 shares of the company were exchanged, compared to its average volume of 8,372,780. Sangamo Therapeutics has a 1-year low of $0.30 and a 1-year high of $3.18. The stock has a market cap of $162.15 million, a price-to-earnings ratio of -0.96 and a beta of 1.57. The company has a 50 day moving average of $0.91 and a 200-day moving average of $1.39.

Institutional Trading of Sangamo Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the stock. E Fund Management Co. Ltd. acquired a new stake in shares of Sangamo Therapeutics during the fourth quarter valued at about $25,000. JPMorgan Chase & Co. increased its holdings in Sangamo Therapeutics by 679.5% in the 4th quarter. JPMorgan Chase & Co. now owns 25,000 shares of the biopharmaceutical company's stock valued at $26,000 after purchasing an additional 21,793 shares during the last quarter. PNC Financial Services Group Inc. raised its position in Sangamo Therapeutics by 2,319.1% in the fourth quarter. PNC Financial Services Group Inc. now owns 26,078 shares of the biopharmaceutical company's stock valued at $27,000 after purchasing an additional 25,000 shares during the period. SBI Securities Co. Ltd. acquired a new position in Sangamo Therapeutics during the fourth quarter worth $28,000. Finally, Shelton Wealth Management LLC purchased a new position in shares of Sangamo Therapeutics during the fourth quarter worth $29,000. 56.93% of the stock is currently owned by hedge funds and other institutional investors.

Sangamo Therapeutics Company Profile

Sangamo Therapeutics, Inc, a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease.